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1. Introduction
1.1. The Bowman-Birk Protease Inhibitor (BBI)
Legume seeds contain different kinds of proteins and protease inhibitors. Serine proteases
are a large sub-group of the protease family [1] and they play a role in various pathological
conditions such as cancer and thrombotic and inflammatory diseases [2]. Thus they are ex‐
cellent targets for treatment of many disorders.
Various plant species and, in particular, legumes contain a great number of serine protease
inhibitors. The Bowman-Birk protease inhibitor belongs to a family of serine protease inhibi‐
tors that has been widely studied for the past 60 years [3, 4].
The soybean-derived Bowman-Birk protease inhibitor (BBI) is a small protein consisting of
71 amino acids and 7 disulfide bonds [4]. BBI is a double-headed serine protease inhibitor,
with two functional active sites at opposite sides of the molecule, which inhibits both trypsin
and chymotrypsin-like proteases [1,3] (Figure 1). It is a water-soluble protein that is resistant
to acidic conditions and proteolytic enzymes [3]. These characteristics make it a good candi‐
date for use as an oral agent for therapeutic purposes.
Crude soybean contains a small amount of BBI and may have components that counter
some of the beneficial effects of BBI. Bowman-Birk Inhibitor Concentrate (BBIC) is a soybean
extract enriched in BBI [5]. Researchers prefer to use BBIC in their studies because a smaller
amount of BBIC contains the proposed dose of BBI compared to crude soybean.
In rodents, BBI is detectable in the blood, tissue and urine after ingestion [6]. Interestingly,
BBI can be detected in the central nervous system (CNS) of animals even when the blood-
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brain barrier is intact. In human studies, although the BBI level could not be detected in
blood after oral BBIC dosing, it could be measured in urine [6].
Figure 1. Crystal structure of soybean-derived Bowman-Birk protease inhibitor
The ability of certain serine protease inhibitors to prevent the malignant transformation of
cells was shown two decades ago [7, 8]. BBI prevents/suppresses carcinogenesis in a variety
of in vitro and in vivo systems [8, 9].
Several human clinical trials to evaluate the effect of BBIC have been completed or are in
progress [10-12]. To date, in completed clinical trials, neither toxicity nor neutralizing anti‐
bodies against BBIC have been reported in patients receiving BBIC [9].
2. Multiple Sclerosis (MS)
MS is the second cause of disability in young adults and is considered to be a demyelinating
disease of the central nervous system (CNS) along with chronic inflammation, demyelina‐
tion and gliosis [13]. Lesions are characterized by periventricular cuffing and infiltration
consisting mainly of T lymphocytes and macrophages, leading to myelin destruction. Re‐
cently neuronal degeneration and axonal involvement have also been shown in MS lesions
[14]. Current findings therefore raise some doubts about the original assumption that MS is
exclusively a white matter disease.
Based on the MS inflammatory phenotype, it has been considered an autoimmune disorder
in which peripherally activated myelin-reactive T cells enter the CNS and begin an immuno‐
logic cascade that subsequently causes myelin damage.
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Activated antigen presenting cells (APCs) and auto-reactive T cells produce pro-inflamma‐
tory cytokines, including IL-23, IFN-γ, TNF-α, IL-17, that enhance cell-mediated immunity
in the CNS [15-17]. Conversely, other cytokines, such as IL-10, IL-27, IL-4 and TGF-β, play
an immunoregulatory role and may be protective in MS [17-20].
Despite extensive research, only a few pharmacotherapeutic agents (e.g., IFN-β, glatiramer
acetate, and mitoxantrone) are available, all of which are administered by injection, demon‐
strate mild to moderate efficacy and have potential side effects [21,22]. A new oral therapeu‐
tic agent (Fingolimod) was approved by the FDA and shows potential benefits in MS
patients [23].
Recently, in two phase three clinical trials, BG-12 (dimethyl fumarate), a newly proposed or‐
al drug for the treatment of multiple sclerosis, showed a significant reduction in relapse rate
and number of MRI lesions in treated patients compared to the placebo group [68, 69].
Development of a new, effective and oral therapy for MS, with fewer side effects, is there‐
fore desirable.
3. Experimental Autoimmune Encephalomyelitis (EAE)
Experimental Autoimmune Encephalomyelitis (EAE) is an autoimmune animal model of
MS. Immunization with myelin peptides in different strains of mice induces chronic or re‐
lapsing types of the disease, which makes EAE a good tool for studying disease mechanisms
and testing therapeutic agents [24] To date, three of the four therapies currently approved
for MS were first tested in this animal model [24].
After immunization with myelin protein, APCs present myelin on the surface of MHC II
and produce pro-inflammatory cytokines. Dendritic cell-derived IL-12 and IL-23 lead to de‐
velopment of myelin-specific Th1 and Th17 cells, respectively. Th1 and Th17 cells are the
two main culprits in pathogenesis of EAE and MS [25]. Auto-reactive T cells enter the CNS
and facilitate recruitment of other immune cells such as monocytes and neutrophils. Accu‐
mulation of inflammatory cells within the CNS promotes myelin damage, axonal loss and
clinical manifestations in affected animals [24].
Recently it has been shown that dendritic cells are also able to produce another cytokine
from the IL-12 family called IL-27. Compared with IL-12 and IL-23, IL-27 elicits different im‐
munoregulatory effects. IL-27 inhibits encephalitogenicity of T cells and suppresses EAE
disease [26]. In addition, it stimulates IL-10 production in T cells and induces Tr1 cells [17].
IL-10 is a widely studied immunoregulatory cytokine, which virtually all immune cells are
able, in different conditions, to release and which suppresses inflammatory response [27].
IL-10 also plays a significant role in suppression of EAE [28-30].
In general, if a therapeutic agent is able to stimulate IL-10 production and Tr1 cells, it could
be an excellent candidate for MS therapy.
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4. Proteases in inflammation
Several proteases are associated with the pathogenesis of inflammatory disorders [24, 31].
Proteolytic enzymes are involved in activation and migration of immune cells, cytokine and
chemokine activation/inactivation and complement function [32].
Various studies demonstrate that neutrophil serine proteases induce proinflammatory activ‐
ity of both IL-32 and IL-33 cytokines [33, 34]. They are also able to convert inactive forms of
IL-1 and IL-18 to the active form of these cytokines [35]. Cytotoxic T cell-derived proteases
called granzymes are also involved in inflammation. Granzymes promote T cell entry into
the site of inflammation. In addition, they stimulate B cell proliferation [36].
The complement cascade contains different enzymes that activate each other and proteases
that play a role in initiation of the cascade, which results in formation of the membrane at‐
tack complex [37].
In general, proteases are involved in all aspects of the immune response and play a signifi‐
cant role in inflammation.
5. Proteases in pathogenesis of EAE and MS
Modulators of neuronal and endogenous proteolysis show a different pattern in spinal cords
of EAE rats compared to control animals. This finding indicates higher activity of some pro‐
teases in EAE than in control groups, which makes specific proteases good potential bio‐
markers for disease activity or therapeutic targets in the EAE model and MS [38]. Various
types of proteases, including lysosomal proteases and matrix metalloproteinases (MMPs),
are highly expressed in MS lesions [24, 39-42]. Serine proteases such as plasmin, cathepsin
G, chymase and trypsin activate inert MMP proenzymes to their active forms [24, 41, 42].
GelatinaseB (MMP-9] increases the number of leukocytes entering the site of inflammation
and promotes myelin breakdown [39, 43]. Plasmin is a serine protease that mainly partici‐
pates in the coagulation cascade. It has been demonstrated that plasmin directly induces
myelin destruction and demyelination [44].
Levels of gelatinase and tissue plasminogen activator (t-PA) are also increased in MS lesions
and in the cerebrospinal fluid (CSF) of active MS patients [46, 47]. Reactive astrocytes and
infiltrating lymphocytes, macrophages and microglia express MMP-2, MMP-9 and t-PA in
early active MS plaques [24, 41, 45, 47].
6. Anti-inflammatory effects of BBI
BBI suppresses the function of several proteases such as leukocyte elastase, trypsin and hu‐
man cathepsin G released from human inflammatory cells. [48-50]. Mast cell chymase stimu‐
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lates migration of lymphocytes and purified T cells, and BBI inhibits this enzyme quite
efficiently [49]. In addition, BBI significantly suppresses the chemotactic activity of chymase,
thus suppressing lymphocyte migration [51].
Stimulated human polymorphonuclear leukocytes produce reactive oxygen species (super‐
oxide and hydrogen peroxide) that may damage cell membranes by reacting with phoso‐
pholipids to form peroxides [52]. BBI is able to suppress the production of reactive oxygen
species and inhibits their destructive effects [53]. Macrophage-derived proteases and free
radicals are also associated with inflammation. BBI down-regulates NO and PGE2 inflam‐
matory pathways in LPS-activated macrophages [54]. Activated macrophages also induce
neurotoxicity in the CNS. Anti-inflammatory effects of BBI prevent macrophage-induced
neurotoxicity [55].
Serine protease inhibitors can prevent conversion of pro-MMPs to enzymatically active
forms [56, 57]. BBI inhibits generation of active MMP-1 and MMP-9 in vitro, and BBIC re‐
duces MMP-2 and -9 activity in supernatants of spleen cells [58].
The aforementioned mechanisms may be particularly relevant in the context of the patho‐
genesis of multiple sclerosis and myelin destruction in the CNS.
BBI may have significant immunomodulatory effects and can be an excellent potential can‐
didate for treatment of inflammatory and autoimmune diseases.
7. BBI and other protease inhibitors in treatment of inflammatory disease
The role of proteases in inflammation has been reviewed in previous sections. Based on the
fact that proteases are actively involved in inflammation, they can be a good therapeutic tar‐
get in suppression of inflammatory response and treatment of inflammatory diseases.
RWJ-355871 is a synthetic protease inhibitor that effectively suppresses allergic inflammato‐
ry diseases of the respiratory system [59]. 4-(2-Aminoethyl) benzenesulfonyl fluoride
(AEBSF) is another protease inhibitor that attenuates ovalbumin-induced allergic airway in‐
flammation in its animal model [60].
Several studies have reported that protease inhibitors diminish inflammatory response in in‐
flammatory bowel diseases [1]. Nafamostat is a serine protease inhibitor that suppresses
dextran sulfate sodium-induced colitis and diminishes inflammatory infiltration in the colon
[61]. BBI is able to suppress gland inflammation in the gastrointestinal tract and shows a
strong anti-inflammatory effect in the acute colitis model [62]. In addition, in a completed
clinical trial [12], BBI demonstrates anti-inflammatory effects and a degree of amelioration of
clinical disease and remission rate in patients with ulcerative colitis. We have also shown
that administration of oral BBIC significantly inhibits experimental autoimmune neuritis
(EAN) in rats [63, 64].
All of the above findings show the potential immunomodulatory and therapeutic effect of
BBI in autoimmune diseases.
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8. Immunoregulatory effect of BBI in the EAE model
We have shown that oral treatment of BBIC in MBP-induced EAE in rats, reduces disease
severity from clinical score 3 (complete hind limb paralysis) to less than 1 (flaccid tail) com‐
pared to control animals. In addition, BBIC treatment significantly diminished demyelina‐
tion in the peripheral nerve tissue of treated animals [58]. We have also shown that both BBI
and BBIC suppress clinical and pathologic manifestations of chronic and relapsing EAE in
B6 and SJL mice. In addition, the therapeutic effect of oral BBI is dose-dependent, and oral
administration of higher amounts of BBI inhibits EAE more efficiently [65] (Figure 1).
BBI treatment also decreased pathogenicity of myelin-reactive T cells and induced milder
disease in the adoptively transferred EAE model (unpublished data).
Figure 2. Effect of oral BBI compared to PBS treatment in EAE. Mice that received BBI showed significantly less severe
disease compared to control group. The therapeutic effect of BBI is dose-dependent. Elsevier Publications Ltd. has
kindly granted us permission to reproduce this figure from Touil et al., 2008.
BBI inhibits invasion of immune cells through the blood-brain barrier (BBB). BBI-treated
mice showed dramatically lower numbers of CNS-infiltrating MNCs than control animals
[58, 65, 66]. In addition, BBI suppresses generation of active MMP-1 and MMP-9 in vitro,
and BBIC reduces MMP-2 and -9 activity in supernatants of spleen cells [58]. Consistent
with other findings, BBI decreased migration of splenocytes in Boyden’s chamber assay [65].
However, BBI may inhibit release of active MMP-2 and MMP-9 at the blood-brain barrier
and prevent immune cell infiltration into the CNS; it might decrease expression of adhesion
molecules on immune cells or invasiveness of immune cells, resulting in an altered cytokine
pattern of inflammatory cells that hinders their migration from peripheral immune organs
to the site of inflammation.
In order to clarify immunoregulatory mechanisms of BBI, the direct effect of BBI on immune
cells was evaluated, and it was shown that splenocytes produce a higher amount of IL-10
following BBI treatment [65, 66]. Several reports have demonstrated the immunoregulatory
effect of IL-10 in the EAE model of multiple sclerosis. To determine whether the immuno‐
modulatory effect of BBI depends on IL-10, we have compared the therapeutic effect of oral
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BBI in EAE in WT and IL-10 KO mice. Although BBI-treated WT mice showed less severe
disease, BBI treatment did not affect clinical disease in BBI-treated IL-10 KO mice compared
to the control group [66] (Figure 3).
Figure 3. Effect of oral BBI compared to PBS treatment in EAE in WT and IL-10 KO mice. Although BBI-treated WT mice
showed significantly less severe disease compared to the control group, there was no significant difference in treated and
control IL-10 KO mice. Figure reproduced from Dai et al., 2012 with the kind permission of Elsevier Publications Ltd.
Different types of immune cells can release IL-10 cytokine [27]. However, BBI treatment in‐
duces IL-10 mainly in CD4+ T cells [66]; it increases IL-10 production in CD8+ T cells (unpub‐
lished data), demonstrating that BBI has a strong ability to activate IL-10 producing
pathways in T cells. Exploring these underlying mechanisms will be a major focus of our fu‐
ture studies.
Figure 4. Higher expression of Foxp3+ Treg cells in CNS infiltrating cells after oral treatment with BBI, Figure repro‐
duced from Dai et al., 2012 with the kind permission of Elsevier Publications Ltd.
Treg cells are a subgroup of CD4+ T cells that expresses the Foxp3+ transcription factor. They
produce IL-10 in the CNS and can suppress EAE disease [67]. Oral administration of BBI al‐
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so induces Treg cells in the CNS, which might be one of the underlying mechanisms of the
therapeutic effect of BBI in EAE [66] (Figure 4)
BBI also induces IL-10 in other types of effector T cells, and the immunomodulatory effect of
BBI might be related to an increase in Tr1 cells. Should this be the case, BBI can be used to in‐
duce regulatory T cells and for treatment of autoimmune diseases such as multiple sclerosis.
9. Conclusion
BBI is a soybean-derived serine protease inhibitor. It can be administered orally with several
immunomodulatory characteristics and no major side effects. Our observations have shown
that BBI dramatically decreases severity of EAE and that its therapeutic effect is mediated
through IL-10. In addition, BBI decreases infiltration of inflammatory cells across the BBB
and inflammation in the CNS. BBI has potential as a safe and effective oral therapy for mul‐
tiple sclerosis and other autoimmune diseases.
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